Zbtb32 enriched in T _tex CD8 ⁺ TILs benefits clinical outcome. (A) Correlations between ZBTB32 expression and T_tex signature score in diverse cancer patients. (B) Correlation between ZBTB32 expression and T_tex signature score in SKCM patients. (C) Correlations between ZBTB32 expression and T_tex signature score in T_tex signature-enriched (blue) and -decreased groups (red) of diverse cancer patients. (D) Correlations of ZBTB32 expression versus T_tex signature score in T_tex signature-enriched and -decreased groups of SKCM patients. (E) The tSNE plot of scRNA-seq dataset indicating global transcriptomic similarities of CD8⁺ TILs in SKCM TME. (F) FeaturePlots showing expression profiles of ZBTB32 and other classic genes in SKCM CD8⁺ TILs. (G) The expression levels of ZBTB32 and other classic genes in the different clusters of SKCM CD8⁺ TILs. (H) The overall survival rates for ZBTB32^high and ZBTB32^low SKCM patients with enriched or decreased CD8⁺ TILs. GEO accessions: (A) and B) GSE182035, (E–G) GSE120575. R square (A), Pearson R (B, C, and D), unpaired two-tailed Student’s t test (C), and Mantel–Cox test (H); ****P < 0.0001.